Related Experiment Video

Updated: Jun 22, 2025

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.1K

Prospects of Disease-Modifying Osteoarthritis Drugs

Win Min Oo1

  • 1Department of Physical Medicine and Rehabilitation, Mandalay General Hospital, University of Medicine, Mandalay, Mandalay, Myanmar; Rheumatology Department, Royal North Shore Hospital, Institute of Bone and Joint Research, Kolling Institute, The University of Sydney, Sydney, Australia.

Rheumatic Diseases Clinics of North America
|June 28, 2024
PubMed

Insights

Osteoarthritis treatments are lacking, but new disease-modifying drugs (DMOADs) targeting inflammation, bone, or cartilage are in development. Research opportunities exist to improve clinical trial design for these promising osteoarthritis therapies.

Area of Science:

  • Rheumatology and Drug Development
  • Biomedical Research and Clinical Trials

Background:

  • Osteoarthritis (OA) presents a significant global health challenge, affecting nearly 23% of the population in 2020.
  • Current OA treatments primarily manage symptoms, with a critical unmet need for disease-modifying osteoarthritis drugs (DMOADs).

Purpose of the Study:

  • To review active DMOAD candidates in Phase 2/3 clinical trials.
  • To analyze these candidates based on key osteoarthritis pathogenetic mechanisms: inflammation-driven, bone-driven, and cartilage-driven endotypes.
  • To identify challenges and research opportunities for advancing OA drug development.

Main Methods:

  • Literature review of DMOAD candidates in late-stage clinical development.
  • Categorization of drug candidates by OA endotype.
  • Framework for research question formulation using the PICO approach (Population, Intervention, Comparison, Outcome).

Main Results:

  • Several DMOAD candidates targeting distinct OA endotypes are progressing through clinical trials.
  • The review highlights the complexity of OA pathogenesis and the need for targeted therapeutic strategies.
  • The PICO approach offers a structured method for designing future OA clinical trials.

Conclusions:

  • Active research into DMOADs offers hope for improved osteoarthritis management.
  • Understanding OA endotypes is crucial for developing effective, targeted therapies.
  • Optimizing clinical trial design through structured approaches like PICO is essential for successful drug development.
Keywords:
DMOADsDisease-modifying drugsIntra-articular therapy: endotypeOsteoarthritis

More Related Videos

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model07:32

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model

Published on: May 6, 2020

12.1K
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

3.8K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
271
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130